NasdaqCM - Delayed Quote USD

Oramed Pharmaceuticals Inc. (ORMP)

2.3500 +0.0200 (+0.86%)
At close: April 23 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Nadav Kidron Esq. President, CEO & Executive Chairman 754.3k -- 1974
Mr. David Silberman CPA CFO & Treasurer 259.53k -- 1984
Dr. Miriam Kidron Ph.D. Chief Scientific Officer & Director 503.95k -- 1940
Mr. Joshua Hexter Chief Operating & Business Officer 326.94k -- 1970

Oramed Pharmaceuticals Inc.

1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
844 967 2633 https://www.oramed.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Corporate Governance

Oramed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Oramed Pharmaceuticals Inc. Earnings Call

Related Tickers

ENLV Enlivex Therapeutics Ltd.
1.3200
+3.94%
 
BLRX BioLineRx Ltd.
0.6368
-5.95%
 
CGEN Compugen Ltd.
1.9800
+4.76%
 
PLUR Pluri Inc.
5.0000
-0.20%
 
EVGN Evogene Ltd.
0.6597
+0.73%
 
CANF Can-Fite BioPharma Ltd.
1.9700
-0.51%
 
IFRX InflaRx N.V.
1.3600
-0.73%
 
ATXI Avenue Therapeutics, Inc.
0.1340
+3.00%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0600
-0.97%
 
ENTX Entera Bio Ltd.
2.2200
+8.29%